Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

NPM-ALK Oncoprotein Suppresses Anti-Tumor Immune Responses Partially through Cgas-Sting Pathway in ALK+ Anaplastic Large Cell Lymphoma

Ioanna Xagoraris, Ying Yang, Dora Trogrlic, Alma Mansson, Christina Plastira, Vasiliki Leventaki, Hong Qian, Andreas Lundqvist, George Z. Rassidakis

Blood (2024) 144 (Supplement 1): 2999.

https://doi.org/10.1182/blood-2024-205772

Published: 2024

Journal Articles

Ex Vivo Activity of Immunotherapeutic Approaches Targeting CD38 Against Daratumumab-Resistant Multiple Myeloma Patient Samples

Maria Karvouni, MSc, PharmD, Heyue Zhou, Arnika Kathleen Wagner, PhD, Qiangzhong Ma, Alamdar H. Baloch, PhD, Tong Zhu, Hong Zhang, Mari Gilljam, Andreas Lundqvist, PhD, Gunnar F. Kaufmann, PhD, Evren Alici, MD PhD

Blood (2019) 134 (Supplement_1): 1848.

https://doi.org/10.1182/blood-2019-127893

Published: 2019

Journal Articles

IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells

Yumeng Mao, Vincent van Hoef, Xiaonan Zhang, Erik Wennerberg, Julie Lorent, Kristina Witt, Laia Masvidal, Shuo Liang, Shannon Murray, Ola Larsson, Rolf Kiessling, Andreas Lundqvist

Blood (2016) 128 (11): 1475–1489.

https://doi.org/10.1182/blood-2016-02-698027

Published: 2016

Includes: Supplemental data

Journal Articles

Regulation of Natural Killer Cell Responses By Dendritic Cells Via Lymphotoxin-Alpha, Interleukin-12, and Tumor Growth Factor-Beta

Dhifaf Sarhan, PhD, Marzia Palma, MD PhD, Yumeng Mao, Lars Adamson, Rolf Kiessling, MD PhD, Håkan Mellstedt, MD PhD, Anders Österborg, Andreas Lundqvist

Blood (2014) 124 (21): 4140.

https://doi.org/10.1182/blood.V124.21.4140.4140

Published: 2014

Journal Articles

A Phase I Trial of Adoptively Transferred Ex-Vivo Expanded Autologous Natural Killer (NK) Cells Following Treatment with Bortezomib to Sensitize Tumors to NK Cell Cytotoxicity

Robert N Reger, Maria Berg, Andreas Lundqvist, PhD, Theresa Donohue, MHS, PA-C, Mattias Carlsten, MD Ph.D, Dawn M Betters, Ph.D, Lisa Cook, RN, BSN, Catalina Ramos, RN, BSN, Sophia Grasmeder, RN, BSN, OCN, Su Su, MD, PhD, David Stroncek, MD, Jeremy Pantin, MD, Keyvan Keyvanfar, BS, Cristian A. Carvallo, MD, Hahn Khuu, MD, Richard Childs, MD

Blood (2011) 118 (21): 1001.

https://doi.org/10.1182/blood.V118.21.1001.1001

Published: 2011

Journal Articles

Optimizing Lentiviral Transduction of Human Natural Killer Cells

Su Su, MD, PhD, Dawn M Betters, Ph.D, Muthalagu Ramanathan, MD, Keyvan Keyvanfar, BS, Aleah Smith, Xingmin Feng, PhD, Elissa Furutani, Mattias Carlsten, MD Ph.D, Andreas Lundqvist, PhD, Richard Childs, MD

Blood (2011) 118 (21): 4714.

https://doi.org/10.1182/blood.V118.21.4714.4714

Published: 2011

Journal Articles

Unlicensed natural born killers

Andreas Lundqvist, Richard Childs

Blood (2011) 117 (26): 6974–6975.

https://doi.org/10.1182/blood-2011-05-350314

Published: 2011

Journal Articles

Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation

Hisayuki Yokoyama, Andreas Lundqvist, Su Su, Richard Childs

Blood (2010) 116 (15): 2858–2859.

https://doi.org/10.1182/blood-2010-06-291104

Published: 2010

Journal Articles

In Vitro Expanded NK Cells Have Increased Natural Cytotoxity Receptors, TRAIL and NKG2D Expression, and Superior Tumor Cytotoxicity Compared to Short-Term IL-2 –Activated NK Cells.

Maria Berg, Andreas Lundqvist, Dawn Betters, Richard W. Childs, MD

Blood (2009) 114 (22): 463.

https://doi.org/10.1182/blood.V114.22.463.463

Published: 2009

Journal Articles

Adoptive Infusion of Ex Vivo Expanded Autologous Natural Killer (NK) Cells in Cancer Patients Treated with Bortezomib to Sensitize to NK-TRAIL Cytotoxicity.

Andreas Lundqvist, M. Berg, A. Smith, L. Cook, R. Goodwin, C. Ramos, S. Vasu, J. Pantin, R. Lopez, H. Khuu, V. Fellowes, D. Stroncek, T. Donohue, R. Childs

Blood (2009) 114 (22): 4080.

https://doi.org/10.1182/blood.V114.22.4080.4080

Published: 2009

Journal Articles

Adoptive Transfer of Natural Killer (NK) Cells to Prevent Gvhd and Enhance GVT Effects After Allogeneic Hematopoietic Cell Transplantation (HCT): The Timing of Donor NK Cell Infusions Critically Impacts Transplant Outcome.

Andreas Lundqvist, Hisayuki Yokoyama, MD, PhD, Richard W. Childs, MD

Blood (2009) 114 (22): 786.

https://doi.org/10.1182/blood.V114.22.786.786

Published: 2009

Journal Articles

Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells

Andreas Lundqvist, Hisayuki Yokoyama, Aleah Smith, Maria Berg, Richard Childs

Blood (2009) 113 (24): 6120–6127.

https://doi.org/10.1182/blood-2008-11-190421

Published: 2009

Journal Articles

Primitive quiescent CD34 + cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib

Agnes S. M. Yong, Keyvan Keyvanfar, Nancy Hensel, Rhoda Eniafe, Bipin N. Savani, Maria Berg, Andreas Lundqvist, Sharon Adams, Elaine M. Sloand, John M. Goldman, Richard Childs, A. John Barrett

Blood (2009) 113 (4): 875–882.

https://doi.org/10.1182/blood-2008-05-158253

Published: 2009

Journal Articles

Lentiviral Transduction of Ex Vivo Expanded Natural Killer Cells with a CD19 Chimeric Antigen Receptor Induces Cytotoxicity against Resistant B Cell Malignancies

Muthalagu Ramanathan, Su Su, Andreas Lundqvist, Maria Berg, Aleah Smith, Rebecca Lopez, Ann Williams, Erkut Bahceci, J. Philip McCoy, Laurent Boissel, Hans-Georg Klingemann, Richard Childs

Blood (2008) 112 (11): 3540.

https://doi.org/10.1182/blood.V112.11.3540.3540

Published: 2008

Journal Articles

A Highly Efficient Method to Expand CD3 - CD56 + NK Cells from Cord Blood Segments

Sumithira Vasu, Maria Berg, Andreas Lundqvist, Muthalagu Ramanathan, Rebecca Lopez, Phil McCoy, Jr, Hua Zhang, Crystal Mackall, Richard Childs

Blood (2008) 112 (11): 3902.

https://doi.org/10.1182/blood.V112.11.3902.3902

Published: 2008

Journal Articles

A Rhesus Macaque Model to Optimize Adoptive NK Cell Therapy

Rebecca Lopez, Andreas Lundqvist, Stephanie Sellers, Maria Berg, Muthalagu Ramanathan, Sumithira Vasu, Aleah Smith, Cynthia E. Dunbar, Richard W. Childs, MD

Blood (2008) 112 (11): 3905.

https://doi.org/10.1182/blood.V112.11.3905.3905

Published: 2008

Journal Articles

Adoptively-Infused NK Cells Maintain Their Antitumor Effects in Vivo in the Presence of CyclosporineA (CSA)

Hisayuki Yokoyama, Andreas Lundqvist, Maria Berg, Muthalagu Ramanathan, Rebecca Lopez, Aleah Smith, Nicole Gormley, Su Su, J. Phillip McCoy, Richard W. Childs, MD

Blood (2008) 112 (11): 2563.

https://doi.org/10.1182/blood.V112.11.2563.2563

Published: 2008

Journal Articles

Bortezomib Enhances the Antitumor Activity of Adoptively Infused Natural Killer Cells In Vivo: A Novel Approach To Override KIR-Mediated Inhibition of NK Cell Cytotoxicity.

Andreas Lundqvist, PhD, Sheila Rao, BS, Aleah Smith, BS, Maria Berg, BS, Su Su, PhD, Hisayuki Yokoyama, PhD, Shivani Srivastava, MD, Richard Childs, MD

Blood (2007) 110 (11): 1786.

https://doi.org/10.1182/blood.V110.11.1786.1786

Published: 2007

Journal Articles

The Proteasome Inhibitor Bortezomib Simultaneously Enhances NK Cell Tumor Cytotoxicity While Paradoxically Reducing Antigen Specific T-Cell Tumor Cytotoxicity.

Andreas Lundqvist, PhD, Sheila Rao, BS, Maria Berg, BS, Aleah Smith, BS, Su Su, PhD, Hisayuki Yokoyama, PhD, Shivani Srivastava, MD, Richard Childs, MD

Blood (2007) 110 (11): 1789.

https://doi.org/10.1182/blood.V110.11.1789.1789

Published: 2007

Journal Articles

Cyclosporine A (CSA) Significantly Reduces the Cytotoxic Effects of In Vitro Expanded NK Cells: Implications for Adoptive NK Cell Therapy in the Setting of Allogeneic Hematopoietic Stem Cell Transplantation (HCT).

Hisayuki Yokoyama, MD, PhD, Maria Berg, Andreas Lundqvist, PhD, J. Philip McCoy, PhD, Shivani Srivastava, MD, Aleah Smith, Richard Childs, MD

Blood (2007) 110 (11): 4899.

https://doi.org/10.1182/blood.V110.11.4899.4899

Published: 2007

NARROW

NPM-ALK Oncoprotein Suppresses Anti-Tumor Immune Responses Partially through Cgas-Sting Pathway in ALK+ Anaplastic Large Cell Lymphoma

Ex Vivo Activity of Immunotherapeutic Approaches Targeting CD38 Against Daratumumab-Resistant Multiple Myeloma Patient Samples

IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells

Regulation of Natural Killer Cell Responses By Dendritic Cells Via Lymphotoxin-Alpha, Interleukin-12, and Tumor Growth Factor-Beta

A Phase I Trial of Adoptively Transferred Ex-Vivo Expanded Autologous Natural Killer (NK) Cells Following Treatment with Bortezomib to Sensitize Tumors to NK Cell Cytotoxicity

Optimizing Lentiviral Transduction of Human Natural Killer Cells

Unlicensed natural born killers

Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation

In Vitro Expanded NK Cells Have Increased Natural Cytotoxity Receptors, TRAIL and NKG2D Expression, and Superior Tumor Cytotoxicity Compared to Short-Term IL-2 –Activated NK Cells.

Adoptive Infusion of Ex Vivo Expanded Autologous Natural Killer (NK) Cells in Cancer Patients Treated with Bortezomib to Sensitize to NK-TRAIL Cytotoxicity.

Adoptive Transfer of Natural Killer (NK) Cells to Prevent Gvhd and Enhance GVT Effects After Allogeneic Hematopoietic Cell Transplantation (HCT): The Timing of Donor NK Cell Infusions Critically Impacts Transplant Outcome.

Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells

Primitive quiescent CD34 + cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib

Lentiviral Transduction of Ex Vivo Expanded Natural Killer Cells with a CD19 Chimeric Antigen Receptor Induces Cytotoxicity against Resistant B Cell Malignancies

A Highly Efficient Method to Expand CD3 - CD56 + NK Cells from Cord Blood Segments

A Rhesus Macaque Model to Optimize Adoptive NK Cell Therapy

Adoptively-Infused NK Cells Maintain Their Antitumor Effects in Vivo in the Presence of CyclosporineA (CSA)

Bortezomib Enhances the Antitumor Activity of Adoptively Infused Natural Killer Cells In Vivo: A Novel Approach To Override KIR-Mediated Inhibition of NK Cell Cytotoxicity.

The Proteasome Inhibitor Bortezomib Simultaneously Enhances NK Cell Tumor Cytotoxicity While Paradoxically Reducing Antigen Specific T-Cell Tumor Cytotoxicity.

Cyclosporine A (CSA) Significantly Reduces the Cytotoxic Effects of In Vitro Expanded NK Cells: Implications for Adoptive NK Cell Therapy in the Setting of Allogeneic Hematopoietic Stem Cell Transplantation (HCT).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only